Moeniralam H S, Endert E, Ackermans M T, Van Lanschot J J, Sauerwein H P, Romijn J A
Department of Internal Medicine, Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands.
Am J Physiol. 1998 Sep;275(3):E440-7. doi: 10.1152/ajpendo.1998.275.3.E440.
Sufentanil is a synthetic mu-opioid receptor agonist frequently used in anesthesia and critically ill patients. To evaluate the effects of sufentanil on the inflammatory, neuroendocrine, and metabolic responses to endotoxin, we studied six dogs during saline infusion (control), during sufentanil infusion (1.5 microg . kg-1 . h-1), after endotoxin injection (1.0 microg/kg iv), and during combined endotoxin and sufentanil administration. The rate of appearance of glucose was determined by infusion of [6,6-2H2]glucose. Sufentanil depressed the endotoxin-induced increase in body temperature (36.9 +/- 0.3 vs. 40.6 +/- 0.5 degrees C, P < 0.05). Sufentanil depressed the tumor necrosis factor (TNF) response to endotoxin by approximately 60% (P < 0.01) but increased the interleukin-6 (IL-6) response by approximately 70% (P < 0.01). Sufentanil per se induced a transient neuroendocrine activation. Sufentanil also increased plasma concentrations of insulin and catecholamines after endotoxin (P < 0.05 vs. endotoxin alone) and increased plasma glucose levels by approximately 36% (from 6.1 +/- 0.1 to 8.3 +/- 0.6 mmol/l, P < 0.05 vs. endotoxin alone). Endotoxin stimulated glucose production transiently by 95% (24.2 +/- 3.2 vs. control 12.4 +/- 1.0 micromol . kg-1 . min-1, P < 0.05). Paradoxically, sufentanil inhibited this endotoxin-induced stimulation of glucose production (P < 0.05 vs. endotoxin alone). In conclusion, sufentanil modulates the response to intravenous endotoxin by dissociating the TNF and IL-6 response, increasing insulin and catecholamine levels, and depressing the increase in glucose production. Therefore, opiates alter inflammatory, endocrine, and metabolic regulation in endotoxemia.
舒芬太尼是一种合成的μ-阿片受体激动剂,常用于麻醉和重症患者。为了评估舒芬太尼对内毒素引起的炎症、神经内分泌和代谢反应的影响,我们对6只犬进行了研究,分别在输注生理盐水(对照)、输注舒芬太尼(1.5微克·千克⁻¹·小时⁻¹)、注射内毒素(1.0微克/千克静脉注射)以及内毒素和舒芬太尼联合给药期间进行观察。通过输注[6,6-²H₂]葡萄糖来测定葡萄糖的生成速率。舒芬太尼抑制了内毒素引起的体温升高(36.9±0.3对40.6±0.5℃,P<0.05)。舒芬太尼使对内毒素的肿瘤坏死因子(TNF)反应降低约60%(P<0.01),但使白细胞介素-6(IL-6)反应增加约70%(P<0.01)。舒芬太尼本身可引起短暂的神经内分泌激活。舒芬太尼还在内毒素注射后增加了胰岛素和儿茶酚胺的血浆浓度(与单独注射内毒素相比,P<0.05),并使血糖水平升高约36%(从6.1±0.1升至8.3±0.6毫摩尔/升,与单独注射内毒素相比,P<0.05)。内毒素使葡萄糖生成短暂增加95%(24.2±3.2对对照12.4±1.0微摩尔·千克⁻¹·分钟⁻¹,P<0.05)。矛盾的是,舒芬太尼抑制了这种内毒素诱导的葡萄糖生成刺激(与单独注射内毒素相比,P<0.05)。总之,舒芬太尼通过分离TNF和IL-6反应、增加胰岛素和儿茶酚胺水平以及抑制葡萄糖生成增加来调节对静脉内毒素的反应。因此,阿片类药物可改变内毒素血症中的炎症、内分泌和代谢调节。